Ocrelizumab (Ocrevus) (Hoffmann-La roche limited).
The objective of this systematic review is to examine the beneficial and harmful effects of ocrelizumab treatment for the suppression of relapses and disease progression in adult patients with relapsing forms of multiple sclerosis (MS).
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534378/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
